The stimulatory activity of PPARγ agonists changes phenotypes and functions of both, malignant and non-malignant cells and their respective ‘communication protocol’ due to the ubiquitous, but differential expression of PPARγ in all cell compartments of the tumor tissue (100). The gene discussed is PPARG; the disease is neoplasm.